News
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
Sonova to increase presence in US market: Acquisition of leading audiological care network
Sonova to increase presence in US market:
Acquisition of leading audiological care network
Sonova verstärkt Präsenz auf dem US-Markt: Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova verstärkt Präsenz auf dem US-Markt:
Akquisition einer führenden Kette von Hörakustikgeschäften
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Sonova nominates Julie Tay for election as a new member of the Board of Directors
EQS-News: Sonova nominates Julie Tay for election as a new member of
the Board of Directors
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
EQS-News: Straumann Group Capital Markets Day 2021
EQS-News: Straumann Group Capital Markets Day 2021
EQS-Adhoc: Evolva announces private placement of 63.8m shares to VERAISON raising gross proceeds of CHF 7.5m and CFO departure
EQS-Adhoc: Evolva announces private placement of 63.8m shares to VERAISON raising gross proceeds of CHF 7.5m and CFO departure
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir